The Compounder (Techni Med, Inc.), Aurora, IL

Is The Compounder (Techni Med, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does The Compounder (Techni Med, Inc.) hold a Illinois pharmacy license?

The Illinois Department of Financial and Professional Regulation lists license 054008872 for TECHNI MED INC (dba THE COMPOUNDER), AURORA, status ACTIVE, as of Nov 13, 2026.

Has The Compounder (Techni Med, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (May 5, 2020), 1 state referral letter (May 5, 2020) and 1 FMD-145 letter (May 5, 2020) for The Compounder (Techni Med, Inc.). State board actions: no Illinois Department of Financial and Professional Regulation action on license 054008872 or under this exact name and city was found in the board’s license dataset (actions dated May 23, 1980 to Sep 10, 2026) on Nov 13, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Techni Med, Inc.; The Compounder
Location
Aurora, IL
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 5, 2020
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 15 observations
State board records
License found: 054008872, ACTIVE

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Techni Med, Inc., (dba The Compounder), a 503A facility, with 4 dated actions.

Document
May 5, 2020Warning letter close-outWarning Letter Close Out Issued 05/05/2020Not linked by FDA
May 5, 2020FMD-145 letterFMD-145 Letter Issued 05/05/2020fda.gov
May 5, 2020State referral letterReferral Letter to the Illinois State Board of Pharmacy Issued 05/05/2020FDA copy (archived)
Oct 10, 2019Form 483483 Issued 10/10/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Techni Med, Inc., Aurora, IL (FEI number 3004504906), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 10, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30045049061106708
Jan 26, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30045049061041122
Jul 9, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI)3004504906933301

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 15 numbered observations in all, across 2 inspections ending Jul 9, 2015 to Oct 10, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 23, 2019 to Oct 10, 2019: 5 observations

Firm on the cover
Techni Med, Inc. dba The Compounder, 340 Marshall Ave Unit 100, Aurora, IL 60506-5649
FEI number
3004504906
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Non-microbial contamination was observed in your production area.

Specifically,

While viewing sterile processing on 9/23/2019, black residue was noted on two white plastic garbage cans, one of which was in the ISO 7 cleamoom and the other which was in the ISO 8 anteroom. In addition, some black residue was obse1ved on the far comer of the ISO 7 cleanroom floor.

Observation 2

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Specifically,

During a certification performed for the cleanroom area on 5-23-2018, out of specification results for viable monitoring in one location of the ISO 8 area and four locations in the ISO 7 area occurred. Although cleaning and routine environmental monitoring of the cleanroom resumed, a follow up certification of the cleanroom was not performed until 9-12-2018. Sterile processing occurred on a routine schedule between 5-23-2018 and 9-12-2018.

Observation 3

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Each batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

Intrathecal products are produced from commercial ingredients that are not indicated for intrathecal use. Endotoxin testing is not routinely performed on all processed intrathecal products. Morphine Sulfate PF 30mg/ml Intrathecal lot 09302019:42@12 was produced on 9/30/2019 for prescription <Redacted B4>. Prescription <Redacted B4> was dispensed on 9/30/2019.

THIS IS A REPEAT OBSERVATION

Observation 4

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically,

Your firm uses non pharmaceutical grade <Redacted B4> as a component of non-sterile pharmaceutical products. Dyclonine HCL Oral Dental (Light Mint)## 1.0% solution lot 10042019:66@2 was produced on 10/4/2019 for prescription number <Redacted B4> Prescription <Redacted B4> was dispensed on 10/8/2019.

Observation 5

Cleaning wipes used in the ISO 5 classified aseptic processing ai·eas were not sterile.

Specifically, on 9-23-2019, during cleaning of the ISO area, non-sterile wipes were used to clean the ISO 5 hoods.

Inspection May 6, 2015 to Jul 9, 2015: 10 observations

Firm on the cover
, Techni Med, Inc. dba The Co mpounder 340 Mars hall Ave Unit 100 CITY, STAT E, ZIP CODE, COUNTRY, Aurora, IL
FEI number
3004504906
Establishment type on the cover
60 506-5649 Producer of Sterile and Non-Steri le Dr ug Pr od ucts
FDA district office on the cover
550 W. Jackson Blvd., Suite 1500; Chicago, IL 60661-4716;
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, the firm does not have adequate control systems in place to ensure sterile drug products are produced under aseptic conditions. The firm's environmental monitoring program does not adequately monitor environmental conditions that could impact aseptic processing operations. For example,

A. The firm does not perform viable or non-viable monitoring inside the IS05 laminar flow hood or adjacent ISO 7 clean room while performing aseptic processing operations. The firm performs viable air monitoring in the ISO 5 zone < Redaction b4> contact sur face sampling <Redaction b4> <Redaction b4> and non-viable monitoring is performed <Redaction b4>.

B. The firm does not perform monitoring on personnel. The firm docs not sample personnel gloves or other locations on personnel such as arm(s) or chest of gowns during routine aseptic processing operations or during media fill studies.

C. The firm has not validated its environmental monitoring microbiological test method to ensure that disinfectan ts used in cleaning will not interfere with recovery of microorganisms.

Observation 2

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, the firm's personnel do not wear sterile gowning during the compounding of sterile drug products. On 05/06/2015, I observed a pharmacy technician wear a non-sterile gown while compounding an intrathecal drug product. Clonidine Batch PF 4mg/ml, lot 05062015:60@20 and on 05/0712015. I observed a pharmacy technician wear a non-sterile gown while compounding an intrathecal drug product. Baclofen 1000mcg/ml lnj. Lot 05072015:88@15.

EUPLOYEE(S) StONA.TUHt O A.~'! lSWEO

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

A. The firm did not adequately validate th at the firm's current aseptic processing conditions will not introduce the potential fo r microbial contamination. Th e firm’s media fill st udies did not adequately simulate the most complex processing co nditions that could provide a challenge to aseptic operations.

B. The firm has not validated the <Redaction b4> sterilization <Redaction b4> that arc used to sterilize drug products such as Progesterone (17 A-Hydroxy) Caproate <Redaction b4> 250mg/ml lnj and Estradiol Valerate in Cottonseed Oil40mg/ml lnj.

C. Dynamic smoke studies have not been performed in the ISO 5 laminar flow hoods to ensure air patterns are suitable for

aseptic conditions.

D. Equipment qualification studies have not performed on the <Redaction b4> used to sterilize drug products.

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

A. The firm does not have established procedures on the frequency of replacing the HEPA filters located in the ISO 5 laminar flow hoods. The firm has not changed out the HEPA filter in its IS05 laminar flow hood <Redac tion b4> since September 2005 and its ISO5 laminar flow hood <Redaction b4> since June 2009.

B. T emperature and pressure are not monitored continuously in the firm's cleanroom complex. T he firm < Redacti on b4> checks both temperature and pressure <Redaction b4>.

~--------------r...u~~~~w~~,s~,.~,u~ ·N~•Tffiu~~.------------------------------------------------------,0~~~~ - ·

Observation 5

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

A. None of the firm's sterile drug products produced in the three months prior to the start of this inspection have been tested for pyrogens. The firm produces sterile drug products that are administered intrathecal, intravenously, and intramuscular.

B. The firm has not validated that its <Redaction b4> microbiological test method used for in-house sterility testing can adequately detect and recover microorganisms. The firm states that they currently use a <Redaction b4> <Redaction b4>. The firm also has not established a written procedure detailing the sterility test method. The firm uses this <Redaction b4> microbiological test method for sterility testing of product lots that are <Redaction b4> and use the <Redaction b4> microbiological test method to determine sterility.

Observation 6

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, the firm does not test its sterile drug products for potency as part of the sterile drug products’ final approval and r elease.

Observation 7

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, the firm has not conducted hold time studies to support the "use by" dates assigned to <Redaction b4> that are stored at refrigerated temperatures. The firm currently assigns a ninety day "beyond use" date for refrigerated <Redaction b4> <Redaction b4> s), which are further used in the production of sterile finished drug products.

For example,

EMPLO~E [S) S IG..,Al i.J'RS.

• <Redaction b4> was produced on 02/12/2015; the assigned "beyond use" date is 05/13/2015;

• <Redaction b4> was produced on 04/12/2015; the assigned "beyond use" date is 07/12/2015;

• <Redaction b4> was produced on 04/13/20 15; the assigned "beyond use" date is 07/12/2015;<Redaction b4> was produced on 04/13/20 15; the assigned "beyond use" date is 07/12/2015;<Redaction b4> was produced on 04/13/20 15; the assigned "beyond use" date is 07/12/2015;<Redaction b4> was produced on 04/13/20 15; the assigned "beyond use" date is 07/12/2015;<Redaction b4> was produced on 04/13/20 15; the assigned "beyond use" date is 07/12/2015;<Redaction b4> was produced on 04/13/20 15; ...

Read the full 483 (PDF on fda.gov)

Observation 8

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, the firm does not have a stability program for its sterile drug products. The firm has not conducted stud ies to support the expiry ("beyond use") dates assigned to its sterile drug products. Fo r example, the firm currently assigns thirty day “be yond use” dates to its sterile i njectable drug pro ducts.

Observation 9

Each lot of a component that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use.

Specifically, the firm has not established incoming specifications for its active pharmaceutical ingredients that are used in the production or sterile drug products. The firm has not established bacterial endotoxin limits or microbial limits for its active pharmaceutical ingredients that are used in the production of its sterile drug products. For example, prior to the start of this inspection, the firm received and accepted Clonidine HCI USP, Baclofen USP, Bupivacaine Hydrochloride USP, Morphine Sulfate USP, and Hydromorphine Hydrochloride USP based on receiving the suppliers' certificates of analysis. The suppliers' certificates of analysis did not include endotoxin and/or microbial limits. For example,

• Clonidine HCI USP, <Redaction b4> certificate of analysis does not include bacterial endotoxin limits or microbial limits:

• Baclofen USP <Redaction b4> 187 certificate of analysis does not include bacterial endotoxin limits or microbial limits: ...

Read the full 483 (PDF on fda.gov)

Observation 10

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

S pecifically, the firm has not validated the efficacy of the sterile <Redaction b4> and <Redaction b4> that are used in the cleaning and disinfection of the firm's ISO 5 laminar flow hoods. The firm has not demonstrated these agent's sporicidal abilities.

Linked 483s whose text is not shown

State board of pharmacy records

The Illinois Department of Financial and Professional Regulation file dated Nov 13, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
054008872LICENSED PHARMACYTECHNI MED INC (dba THE COMPOUNDER)AURORAACTIVE

What this covers: Discipline IDFPR publishes with each license in the dataset (case number, action, start date and the department’s one-line reason), worded as the department gives it. The dataset marks 931 of these licenses as ever disciplined; some of them carry no action in the dataset. Actions in the data are dated May 23, 1980 to Sep 10, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.